{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:30:01Z","timestamp":1794072601578,"version":"4.8.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This review examines the evolving first-line immunotherapy landscape in metastatic renal cell carcinoma (mRCC), with emphasis on the comparative clinical logic of dual immune checkpoint blockade (ICI-ICI) and immune checkpoint inhibitor-tyrosine kinase inhibitor combinations (ICI-TKI), the persistent efficacy-effectiveness gap, biomarker development, and translational resistance biology. Pivotal phase III trials have established superior survival for contemporary ICI-based regimens over sunitinib; however, cross-trial heterogeneity, differences in IMDC risk distribution, varying toxicity profiles, and selection of fitter trial populations complicate simple regimen ranking. Real-world studies confirm that outcomes in routine practice are frequently less favorable than those reported in registration studies, but these differences are partly explained by confounding related to performance status, comorbidity burden, access to care, toxicity management, and treatment sequencing. Renal cell carcinoma remains a biomarker-challenged disease in which PD-L1 and tumor mutational burden have limited predictive value, while PBRM1 status, VHL-driven pseudohypoxia, and spatial immune architecture are biologically informative but not yet clinically validated as stand-alone selection tools. Resistance arises through tumor-intrinsic metabolic reprogramming, impaired antigen presentation, compensatory checkpoint signaling, and stromal-myeloid exclusion within the tumor microenvironment. Taken together, the field is moving from empirical regimen selection toward a model that integrates disease tempo, patient fitness, translational biomarkers, and mechanism-based sequencing. Future progress will depend on composite biomarker validation, biomarker-enriched trials, rational resistance-directed combinations, and structural measures that improve external validity and equitable access.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1715874","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:45Z","timestamp":1776662625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in immunotherapy for renal cell carcinoma: a comprehensive review"],"prefix":"10.3389","volume":"17","author":[{"given":"Emad","family":"Rajih","sequence":"first","affiliation":[{"name":"General and Specialized Surgery Department, Taibah University College of Medicine","place":["Medina, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Bakhsh","sequence":"additional","affiliation":[{"name":"General and Specialized Surgery Department, Taibah University College of Medicine","place":["Medina, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa M.","family":"Borhan","sequence":"additional","affiliation":[{"name":"Basic Medical Sciences Department, Taibah University College of Medicine","place":["Medina, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed Awad M.","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Basic Medical Sciences Department, Taibah University College of Medicine","place":["Medina, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.2648","article-title":"The immunobiology of kidney cancer","volume":"36","author":"Drake","year":"2018","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-93339-9_6","article-title":"Advances in the treatment of metastatic renal cell carcinoma","volume-title":"Genitourinary cancers","author":"Bergerot","year":"2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11912-019-0779-1","article-title":"Current status and future directions of immunotherapy in renal cell carcinoma","volume":"21","author":"Considine","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3233\/KCA-200088","article-title":"Evolving frontline treatment landscape for advanced or metastatic renal cell carcinoma","volume":"4","author":"Jain","year":"2020","journal-title":"Kidney Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/iju.IJU_153_20","article-title":"CheckMate 214 trial: immune checkpoint regulators for advanced renal cell carcinoma","volume":"36","author":"Jena","year":"2020","journal-title":"Indian J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202507.2249.v1","article-title":"A review of immunotherapy in renal cell carcinoma: current landscape and future directions","volume":"17","author":"Peshin","year":"2025","journal-title":"Preprint"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"D\u00edaz-Montero","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0499","article-title":"Tumor microenvironment dynamics in clear-cell renal cell carcinoma","volume":"9","author":"Vuong","year":"2019","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2020.16","article-title":"Resistance to cancer immunotherapy in metastatic renal cell carcinoma","volume":"3","author":"Moreira","year":"2020","journal-title":"Cancer Drug Resistance"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4505\u2013","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","article-title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221108685","article-title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","volume":"14","author":"Lalani","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3233\/KCA-210120","article-title":"First-line immunotherapy combinations in advanced renal cell carcinoma: a rapid review and meta-analysis","volume":"5","author":"Shpilsky","year":"2021","journal-title":"Kidney Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2021-0301","article-title":"Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer","volume":"14","author":"Aragon-Ching","year":"2022","journal-title":"Future Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0007-4551(22)00236-3","article-title":"Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma","volume":"109","author":"Flippot","year":"2022","journal-title":"Bull du Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1255577","article-title":"Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2193528","article-title":"Update on combined immunotherapy for the treatment of advanced renal cell carcinoma","volume":"19","author":"Gebrael","year":"2023","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae181.025","article-title":"6 durable response to immunotherapy-based regimens for IMDC favorable risk patients with metastatic clear cell renal cell carcinoma: a pooled analysis of four published randomized control phase 3 trials","volume":"29","author":"Jang","year":"2024","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"367\u2013","DOI":"10.1200\/JCO.2024.42.4_suppl.367","article-title":"Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients","volume":"42","author":"Beltran-Bless","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.v11i3.352","article-title":"Clinical outcomes for metastatic renal cell carcinoma (mRCC) patients ineligible for front-line clinical trials","volume":"11","author":"Reynolds","year":"2024","journal-title":"J Kidney Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.15586\/jkcvhl.v12i2.387","article-title":"First-line ipilimumab with nivolumab versus immune checkpoint inhibitors with tyrosine kinase inhibitors in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma","volume":"12","author":"Ostrowski","year":"2025","journal-title":"J Kidney Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.07.003","article-title":"Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk International Metastatic Renal Cell Carcinoma Database Consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group","volume":"7","author":"Santoni","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.11.013","article-title":"Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status","volume":"180","author":"Carril-Ajuria","year":"2023","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-024-02473-6","article-title":"Das nicht-klarzellige nierenzellkarzinom","volume":"63","author":"Ahrens","year":"2024","journal-title":"Die Urologie"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020326","article-title":"Immune-based and novel therapies in variant histology renal cell carcinomas","volume":"17","author":"Miller","year":"2025","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","first-page":"353\u2013","DOI":"10.1200\/JCO.2022.40.6_suppl.353","article-title":"A systematic review of immune checkpoint inhibitors (ICI) in non-clear cell renal cell cancer (nccRCC) subtypes","volume":"40","author":"Reis","year":"2022","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2\u2013","DOI":"10.1200\/JCO.2024.42.4_suppl.2","article-title":"First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study","volume":"42","author":"Voss","year":"2024","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4518\u2013","DOI":"10.1200\/JCO.2023.41.16_suppl.4518","article-title":"First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: results of the phase 2 KEYNOTE-B61 study","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0218","article-title":"The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1\/PD-L1 inhibitors","volume":"15","author":"Nuvola","year":"2023","journal-title":"Immunotherapy"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0314-1","article-title":"Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond","volume":"6","author":"Zhu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12154987","article-title":"Biomarkers for immune checkpoint inhibitors in renal cell carcinoma","volume":"12","author":"Martin","year":"2023","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0267","article-title":"Established and emerging biomarkers of immunotherapy in renal cell carcinoma","volume":"16","author":"Jani","year":"2024","journal-title":"Immunotherapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/14737140.2025.2457373","article-title":"Persisting challenges in the development of predictive biomarkers for immuno-oncology therapies for renal cell carcinoma","volume":"25","author":"Kato","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21294\/1814-4861-2023-22-4-109-117","article-title":"Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer","volume":"22","author":"Izmailov","year":"2023","journal-title":"Siberian J Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","article-title":"Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance","volume":"18","author":"Fiori","year":"2019","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13073-018-0598-2","article-title":"Acquired mechanisms of immune escape in cancer following immunotherapy","volume":"10","author":"Iorgulescu","year":"2018","journal-title":"Genome Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.32948\/auo.2025.06.02","article-title":"Metabolic reprogramming in kidney cancer: implications for therapy","volume":"30","author":"Edo","year":"2025","journal-title":"Ann Urologic Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/genes16010006","article-title":"Hypoxia-inducible factor in renal cell carcinoma: from molecular insights to targeted therapies","volume":"16","author":"Roviello","year":"2024","journal-title":"Genes"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.03.001","article-title":"Targeting CAFs to overcome anticancer therapeutic resistance","volume":"8","author":"Saw","year":"2022","journal-title":"Trends Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.47","article-title":"Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena","volume":"6","author":"Roy","year":"2023","journal-title":"Cancer Drug Resistance"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000185","article-title":"Molecular and metabolic basis of clear cell carcinoma of the kidney","volume":"25","author":"Akhtar","year":"2018","journal-title":"Adv Anatomic Pathol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40170-016-0154-8","article-title":"Novel drugs that target the metabolic reprogramming in renal cell cancer","volume":"4","author":"Van Der Mijn","year":"2016","journal-title":"Cancer Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bju.15506","article-title":"Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy","volume":"129","author":"Ambrosetti","year":"2022","journal-title":"BJU Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.05.023","article-title":"Novel immune therapies for renal cell carcinoma","volume":"37","author":"Saad","year":"2023","journal-title":"Hematology\/Oncology Clinics North America"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2308097","article-title":"A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance","volume":"25","author":"Santiago-S\u00e1nchez","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/10255842.2025.2495299","article-title":"Identification of cancer-associated fibroblast characteristics for predicting outcome and response to immunotherapy in renal cell carcinoma","author":"Zhou","year":"2025","journal-title":"Comput Methods Biomech BioMed Eng"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235873","article-title":"The extracellular matrix environment of clear cell renal cell carcinoma determines cancer associated fibroblast growth","volume":"13","author":"Bond","year":"2021","journal-title":"Cancers"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.604627","article-title":"Identification of a gene signature for renal cell carcinoma-associated fibroblasts mediating cancer progression and affecting prognosis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.12.130","article-title":"Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma","volume":"7","author":"Shaya","year":"2019","journal-title":"Ann Trans Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.718014","article-title":"Cost-effectiveness of frontline treatment for advanced renal cell carcinoma in the era of immunotherapies","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(18)33792-8","article-title":"A cost-effectiveness analysis of nivolumab and ipilimumab versus sunitinib in first line intermediate-poor risk advanced renal cell carcinoma","volume":"17","author":"Reinhorn","year":"2018","journal-title":"Eur Urol Suppl"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00447","article-title":"Cost-effectiveness analysis of six immunotherapy-based regimens and sunitinib in metastatic renal cell carcinoma: A public payer perspective","volume":"19","author":"Yoo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B55","doi-asserted-by":"publisher","first-page":"28\u2013","DOI":"10.1200\/OP.2023.19.11_suppl.28","article-title":"Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy","volume":"19","author":"Rahman","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B56","doi-asserted-by":"publisher","first-page":"651\u2013","DOI":"10.1200\/JCO.2023.41.6_suppl.651","article-title":"Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy","volume":"41","author":"Staehler","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1715874\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:46Z","timestamp":1776662626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1715874\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1715874"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1715874","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1715874"}}